The laws and policies for informed consent and other aspects of participant safety in clinical trials receive considerable attention. Equally important are laws designed to ensure that trial participation advances medical science—because this potential benefit is what makes even the smallest set of risks acceptable. The Food and Drug Administration Amendments Act (FDAAA), subsequently clarified by 2017 regulations known as the Final Rule,1 requires trial registration and results reporting. The goal is to ensure that each trial contributes accurate and complete information to the medical evidence base—eliminating “secret trials” or biased reports with misleading conclusions.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Zarin DA, Califf RM. Trial Reporting and the Clinical Trials Enterprise. JAMA Intern Med. 2021;181(8):1131–1132. doi:10.1001/jamainternmed.2021.2041
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.